In the present study, we report on 62 patients with SM-AHNMD with the following aims: 1/ To describe the clinical and laboratory characteristics of myeloid and lymphoid AHNMD patients; 2/ To evaluate the occurrence of genetic mutations such as KIT D816V and JAK2 V617F as well as TET-2, ASXL1, and CBL; 3/ To evaluate a possible impact of these genetic mutations on the clinical and laboratory characteristics of SM-AHNMD patients as well as on their prognosis. Here, JAK2 is linked to systemic mastocytosis.